NEW DDMoRe course Cardiac Safety : 18-22 Jan 2016 (extended deadline, Friday 18 Dec 2015)

Model-Informed Drug Discovery and Development in Cardiac Safety Apply here for DDMoRe Cardiac Safety http://www.ddmore.eu/model-informed-drug-development-safety This public Pharma lead DDMoRe course in Cardiac Safety evaluation is one in a series of comprehensive face-to-face courses introducing the principles of model-informed drug discovery and development, covering a range of therapeutic areas, via the newly-developed DDMoRe interoperability framework. The Department of Quantitative Clinical Pharmacology, AstraZeneca R&D Gothenburg, Sweden together with the Institute of Pharmacy, Freie Universitaet Berlin, Germany are happy to invite you to the following face-to-face course: "Model-informed Drug Development in Cardiac Safety" Dates: 18-22 January 2016 Venue: AstraZeneca R&D Gothenburg site, Pepparedsleden 1, Mlndal, Sweden Intended for: PhD students and Postdoctoral fellows doing research in the quantitative life sciences field, but also open (if places will be available) to other scientists affiliated to the institutions part of the DDMoRe consortium. Topics: Model-informed drug discovery and development to evaluate cardiac safety risks and with an introduction to the DDMoRe framework (new modelling & simulation language, model repository, interoperability platform) Program: Lectures, hands-on sessions, student group work, workshop, and student presentations Course directors: Charlotte Kloft, Zinnia Parra-Guillen, Amy Cheung, Corina Dota Fee: Free of charge (transport, accommodation and food not included) Maximum number of participants: 20 (If needed, selection will be based on the registration information, with priority to PhD students/post-docs and participants from different institutions). New Application deadline: Friday, 18 December 2015 Contact: info.ddmore_at_gmail.com<mailto:info.ddmore_at_gmail.com> For more information: On DDMoRe and the 'education & training activities, read here: http://www.ddmore.eu/model-informed-drug-development-safety We warmly invite you to join us for this public Pharma lead DDMoRe course: be among the first trained for using DDMoRe products! ________________________________ AstraZeneca UK Limited is a company incorporated in England and Wales with registered number: 03674842 and a registered office at 2 Kingdom Street, London, W2 6BD. Confidentiality Notice: This message is private and may contain confidential, proprietary and legally privileged information. If you have received this message in error, please notify us and remove it from your system and note that you must not copy, distribute or take any action in reliance on it. Any unauthorised use or disclosure of the contents of this message is not permitted and may be unlawful. Disclaimer: Email messages may be subject to delays, interception, non-delivery and unauthorised alterations. Therefore, information expressed in this message is not given or endorsed by AstraZeneca UK Limited unless otherwise notified by an authorised representative independent of this message. No contractual relationship is created by this message by any person unless specifically indicated by agreement in writing other than email. Monitoring: AstraZeneca UK Limited may monitor email traffic data and content for the purposes of the prevention and detection of crime, ensuring the security of our computer systems and checking compliance with our Code of Conduct and policies.